Virica Logo
Loading...
Latest News2021-11-12T15:40:50-05:00

Virica Biotech Announces Collaboration with the Government of Canada

For Immediate Release Virica Biotech Announces Collaboration with the Government of Canada to Make Gene Therapies More Accessible and Affordable for Canadians  Download full press release here. Ottawa, Canada – May 2, 2022 –Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, today announced it has received $400,000 from Innovation, Science and Economic Development Canada (ISED) through the Innovative Solutions Canada (ISC) program. This funding supports Virica’s collaboration with the National Research Council of Canada’s (NRC) Cell and Gene Therapy Challenge program to enhance the manufacturing of an affordable version of AAV-LPL, a gene therapy [...]

May 2nd, 2022|

Virica Biotech Announces R&D Partnership with Oxford BioMedica

OTTAWA ,Canada– January 24th, 2022 – Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica's next generation lentiviral vector gene therapies using Virica's Viral Sensitizers (VSEs™). DOWNLOAD FULL PRESS RELEASE HERE

January 24th, 2022|

Virica Biotech Raises Series A Financing & Expands Operations to Support Clients’ Manufacturing of Viral Medicines

OTTAWA – October 4, 2021 – Virica Biotech Inc., a leading life science developer of solutions for scaling of viral medicines, announced today the first closing of its Series A financing. The round, led by Dynamk Capital, is expected to close with additional investors by the end of Q4-2021. The investment strengthens Virica’s already impressive growth trajectory, as it gears up to become a premier manufacturing partner for global viral medicine producers. The investment will be used to expand Virica’s operations with the opening of a new lab facility, that is part of the Ottawa Health Innovation Hub. Watch the grand [...]

October 27th, 2021|

Virica Biotech: Enabling Vaccine Development to Fight Against COVID-19

March 14, 2020—As the world deals with COVID-19, now officially deemed a pandemic, many groups are racing against the clock to develop vaccines against the novel coronavirus. The development and manufacturing of effective vaccines is a laborious and challenging task for a variety of reasons. In the pandemic situation that we and our loved ones are facing today, creating, manufacturing, testing, and delivering novel vaccines for a global population of more than 7 billion is truly a daunting challenge. As researchers and global citizens, we offer our heartfelt thanks to healthcare workers, researchers, governments, and biotechnology companies, who are [...]

November 10th, 2020|

Virica’s Founder and CEO Dr. Jean-Simon Diallo Spoke with CBC’s All in a Day, Alan Neal

Virica’s Founder and CEO Dr. Jean-Simon Diallo spoke in an interview with CBC on All in a Day with Alan Neal on fighting the current COVID-19 pandemic by speeding up the process of mass-producing vaccines. Virica’s VSE technology which was spun out of the Ottawa Hospital Research Institute aims to overcome the manufacturing challenges that exist in producing viruses.

November 10th, 2020|

Breakthrough technology is both intimidating and exhilarating

To achieve the promise of viral medicine, though, the innovation of many is needed. We’re here to guide the way. Let our scientific experience and expertise support you, your science and your business. Let’s talk.

Have a question? Contact Virica
Go to Top